Investment in radiotherapy infrastructure positively affected the economic status of an oncology hospital

Reports of Practical Oncology and Radiotherapy

Volumn 17, Issue 3, 2012, Pages 151-156

  Śmigielska, Mirella ^a   Milecki, Piotr ^a,b  

^a GREATER POLAND CANCER CENTRE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Economic analysis; Investment; Organization and management; Radiotherapy

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; HEALTH ECONOMICS; HUMAN; INCOME; INTENSITY MODULATED RADIATION THERAPY; ONCOLOGY; REIMBURSEMENT;

EID: 84862610537     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpor.2012.01.010     Document Type: Article

References (20)

1. Jena A.B., Philipson T.J. Cost-effectiveness analysis and innovation. J Health Econ 2008, 27:1224-1236.
2. Bentzen S.M. Randomized controlled trials in health technology: overkill or overdue?. Radiother Oncol 2008, 86:141-147.
3. Halperin E.C. Randomized prospective trials of innovative radiotherapy technology are necessary. J Am Coll Radiol 2009, 6:33-37.
4. Vikram B., Coleman C.N., Deye J.A. Current status and future potential of advanced technologies in radiation oncology. Part 1. Challenges and resources. Oncology 2009, 23:379-383.
5. Thomas A. A general inductive approach for qualitative data analysis 2003, University of Auckland, New Zealand, www.health.auckland.ac.nz.
6. Tsanakas A., Desli E. Measurement and pricing of risk in insurance markets. Risk Anal 2005, 5:1653-1668.
7. Ford R. Complex leadership competency in health care: towards framing a theory of practice. Health Serv Manage Res 2009, 22:101-114.
8. Szende A., Mogyorosy Z. Health care provider payment mechanisms in the new EU members of Central Europe and the Baltic states. Eur J Health Econ 2004, 5:259-262.
9. Bentzen S., Heeren G., Cottier B., et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 2005, 75:355-365.
10. Arrow K.J. A difficulty in the concept of social welfare. J Polit Econ 1950, 58:328-346.
11. Aho Group, 2006. Creating an Innovative Europe, Report of the Independent Expert. Group on R&D and Innovation appointed following the Hampton Court Summit. http://europa.eu.int/invest-in-research/.
12. Baaij M., Greeven M., Van Dalen J. Persistent superior economic performance, sustainable competitive advantage, and schumpeterian innovation. Eur Manag J 2004, 5:517-531.
13. Lievens Y., Dunscombe P. Cost of quality: health technology assessment. Quality and safety in radiotherapy 2011, 53-57. CRC Press, Boca raton. T. Pawlicki, P.B. Dunscombe, A.J. Mundt, P. Scalliet (Eds.).
14. Amols H.I. New technologies in radiation therapy: ensuring patient safety, radiation safety and regulatory issues in radiation oncology. Health Phys 2008, 95:658-665.
15. Grant W., Shiao Y.W. Clinical and financial issues for intensity-modulated radiation therapy delivery. Semin Radiat Oncol 1999, 9:99-107.
16. Bogusz-Czerniewicz M., Swiezewski A., Malicki J. The influence of legislative changes on quality and costs in radiotherapy. Rep Pract Oncol Radiother 2008, 13:280-286.
17. Kowalik A., Konstanty E. Basic tests in mammography as a tool in quality improvement. Rep Pract Oncol Radiother 2010, 15(5):145-152.
18. Malicki J., Litoborski M., Bogusz-Czerniewicz M., Swiezewski A. Cost-effectiveness of the modifications in the quality assurance system in radiotherapy in the example of in vivo dosimetry. Phys Med 2009, 25(December (4)):201-206.
19. Malicki J. Staffing for quality: overwiew. Quality and Safety in Radiotherapy 2010, Taylor & Francis. T. Pawlicki, P. Dunscombe, A. Mundt, P. Scalliet (Eds.).
20. Cerezo L. Radiation accidents and incidents. What do we know about the medical management of acute radiation syndrome?. Rep Pract Oncol Radiother 2011, 16(4):119-122.